Fmr LLC Allakos Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Allakos Inc. stock. As of the latest transaction made, Fmr LLC holds 4,684,624 shares of ALLK stock, worth $2.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,684,624

Previous 2,289,102 104.65%

Holding current value

$2.81 Million

Previous $2.88 Million 62.41%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.0 - $1.45 $2.4 Million - $3.47 Million	2,395,522 Added 104.65%	4,684,624 $4.68 Million
Q1 2024 May 13, 2024	BUY	$1.02 - $3.23 $231,516 - $733,135	226,977 Added 11.01%	2,289,102 $2.88 Million
Q4 2023 Feb 13, 2024	BUY	$1.72 - $3.18 $3.26 Million - $6.02 Million	1,894,096 Added 1127.24%	2,062,125 $5.63 Million
Q3 2023 Nov 13, 2023	BUY	$2.13 - $5.55 $111,424 - $290,331	52,312 Added 45.21%	168,029 $381,000
Q2 2023 Aug 11, 2023	BUY	$3.6 - $5.25 $25,131 - $36,650	6,981 Added 6.42%	115,717 $504,000
Q1 2023 May 11, 2023	BUY	$4.3 - $8.27 $4,416 - $8,493	1,027 Added 0.95%	108,736 $483,000
Q4 2022 Feb 13, 2023	BUY	$5.66 - $8.42 $2,626 - $3,906	464 Added 0.43%	107,709 $906,000
Q3 2022 Nov 10, 2022	SELL	$3.02 - $6.12 $2,120 - $4,296	-702 Reduced 0.65%	107,245 $656,000
Q2 2022 Aug 12, 2022	BUY	$2.6 - $6.14 $6,502 - $15,356	2,501 Added 2.37%	107,947 $338,000
Q1 2022 May 13, 2022	BUY	$5.08 - $9.81 $503,605 - $972,514	99,135 Added 1570.83%	105,446 $601,000
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $20.2 Million - $264 Million	-2,358,930 Reduced 99.73%	6,311 $62,000
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $157 Million - $227 Million	2,052,502 Added 656.3%	2,365,241 $250 Million
Q2 2021 Aug 13, 2021	BUY	$85.37 - $114.1 $26.7 Million - $35.7 Million	312,739 New	312,739 $26.7 Million

Others Institutions Holding ALLK

# of Institutions

104

Shares Held

70.7M

Call Options Held

43.8K

Put Options Held

1.4K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $50.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account